Pharmaceutical and biopharmaceutical companies large and small are increasingly relying on third-party providers for support at all stages of drug development. To realize efficiencies, they are at the same time reducing the number of suppliers to a preferred few with whom they can form strategic partnerships.
Review the business development cycle in the custom manufacturing industry and assess risks associated with pharmaceutical fine chemicals manufacturing
Peter Pollak and Andrew Badrot, CMS Pharma10.09.13